AMG
63
3
BBY
49
3
MPC
39
-2
WYNN
29
-3
HOG
45
2
ABBV
55
-4
TAP
66
2
SJM
34
-2
R
70
5
XRAY
19
3
AAPL
46
-10
TSCO
63
3
NEM
48
2
BAX
48
-2
EMR
45
3
QRVO
19
12
AXP
63
4
LNC
58
8
DE
55
-5
FOX
73
3
AMG
63
3
BBY
49
3
MPC
39
-2
WYNN
29
-3
HOG
45
2
ABBV
55
-4
TAP
66
2
SJM
34
-2
R
70
5
XRAY
19
3
AAPL
46
-10
TSCO
63
3
NEM
48
2
BAX
48
-2
EMR
45
3
QRVO
19
12
AXP
63
4
LNC
58
8
DE
55
-5
FOX
73
3
Financhill
Back

Neurocrine Biosciences Stock Predictions

The Tariff-Proof Asset in Your Pocket

This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.
Sell
37

NBIX
Neurocrine Biosciences

Last Price:
$104.21
Seasonality Move:
6.8%

7 Day Trial

ALL ACCESS PASS

$ 7

Meet the founder that's revolutionizing smartphones

This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.

Neurocrine Biosciences Stock Forecast

  • Over the next 52 weeks, Neurocrine Biosciences has on average historically risen by 35.1% based on the past 28 years of stock performance.
  • Neurocrine Biosciences has risen higher in 17 of those 28 years over the subsequent 52-week period, corresponding to a historical accuracy of 60.71%
  • Is Neurocrine Biosciences Stock Undervalued?
    The current Neurocrine Biosciences [NBIX] share price is $108.31. The Score for NBIX is 37, which is 26% below its historic median score of 50, and infers higher risk than normal.
  • NBIX is currently trading in the 30-40% percentile range relative to its historical Stock Score levels.

Will Neurocrine Biosciences Stock Go Up Next Year?

  • Over the next 52 weeks, Neurocrine Biosciences has on average historically risen by 35.1% based on the past 28 years of stock performance.

Neurocrine Biosciences Stock Rating

Sell
37
Neurocrine Biosciences (NBIX) is a Sell

Is Neurocrine Biosciences overpriced?

  • Neurocrine Biosciences has risen higher in 17 of those 28 years over the subsequent 52-week period, corresponding to a historical accuracy of 60.71%

Neurocrine Biosciences Stock Price History

Is NBIX stock going to rise?

  • Based on the share price being below its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bearish and NBIX is experiencing buying pressure, which is a positive indicator for future bullish movement.

Stock Information

Stock Info

Exchange:
NASDAQ
Country:
United States
Industry:
Biotechnology
Sector:
Health Care
Type:
stock
Website:
neurocrine.com

52-Week Data

52-Week High:
157.98
52-Week Low:
105.18

Prediction Charts

Market Cap:
10.8B
Price in USD:
108.31
Volume:
1.4M
Beta:
0.78

Technical Analysis

SMA50:
123.79
SMA100:
127.17
SMA200:
129.54
52-Wk Change:
-21.37%

Stock Predictions

  • Is Neurocrine Biosciences stock public?
    Yes, Neurocrine Biosciences is a publicly traded company.
  • What is the Neurocrine Biosciences stock quote today?
    The Neurocrine Biosciences stock price is 108.31 USD today.
  • How to buy Neurocrine Biosciences stock online?
    You can buy Neurocrine Biosciences shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.

14-Day Historical Data

Date Opening Closing Minimum Maximum
Mar-14 109.00 110.75 111.27 108.03
Mar-17 110.29 111.50 112.74 109.68
Mar-18 111.12 109.70 111.12 109.43
Mar-19 109.70 110.31 110.69 109.47
Mar-20 109.86 110.07 111.25 109.83
Mar-21 109.39 111.92 112.53 109.34
Mar-24 112.65 115.60 115.76 112.59
Mar-25 115.33 116.18 116.23 114.45
Mar-26 116.23 114.45 116.23 113.05
Mar-27 114.47 114.00 115.80 113.55
Mar-28 113.36 113.16 114.43 112.15
Mar-31 111.55 110.60 112.60 109.00
Apr-1 110.59 107.00 110.89 106.49
Apr-2 105.94 108.31 108.43 105.78

Neurocrine Biosciences Earnings

Neurocrine Biosciences Earnings Report: Per Share Neurocrine Biosciences Earnings Q1 Q2 Q3 and Q4 last year and next year.

Neurocrine Biosciences Forecast Revenue Growth

Neurocrine Biosciences Stock Analysis: Historical quarterly revenues per share for Neurocrine Biosciences and historical quarterly revenue growth:

  • Analysts estimate an earnings decrease this quarter of $0.11 per share, an increase next quarter of $0.52 per share, a decrease this year of $0.39 per share, and an increase next year of $2.61 per share.

* Neurocrine Biosciences stock forecasts short-term for next days and weeks may differ from long term prediction for next month and year based on timeline differences.